Of 121 enrolled patients thus far, 109 were included in the safety analysis. Their median age was 14 years. Diazepam nasal spray was administered as needed to treat bouts of diagnosed seizures over a 12-month period. Doses were 5, 10, 15, or 20 mg based on age and body weight. A total of 1,585 seizure episodes were treated with diazepam nasal spray (1 to >40 doses). A single dose adequately controlled seizures in 92% of seizure episodes. Overall, 67 patients had at least one adverse event. A total of 19 patients had treatment-related adverse events, the most frequent of which was nasal discomfort (n=7); 18 patients had 30 serious adverse events that were not treatment-related.
1. Sperling M,et al. AAN 2019, P1.5-028.
Posted on
Previous Article
« Sequencing of high-efficacy disease-modifying treatments in MS Next Article
T-type-calcium channel modulator in essential tremor »
« Sequencing of high-efficacy disease-modifying treatments in MS Next Article
T-type-calcium channel modulator in essential tremor »
Table of Contents: AAN 2019
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer's Disease and other Dementias
Amyloid PET in cognitively impaired patients
Tight blood pressure control lowers risk of mild cognitive impairment
Epilepsy
Headache and Migraine
Multiple Sclerosis and NMOSD
Immune tolerance by peptide-loaded tolerogenic dendritic cells
Biotin, ocrelizumab, and ibudilast in progressive MS
No increased MS relapse risk postpartum
Neuromuscular Disorders
First-ever effective and safe treatment of CMT1A
Parkinsonās Disease and other Movement Disorders
Leukaemia and hypertension therapies tested in Parkinson’s disease
Stroke
Miscellaneous
Possibly lifesaving therapy in refractory PML
New AAN guideline for treating Tourette syndrome
Subspecialty teleneurology: feasible and highly valued
Related Articles

July 30, 2019
Letter from the Editor
July 30, 2019
New AAN guideline for treating Tourette syndrome
July 30, 2019
T-type-calcium channel modulator in essential tremor
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com